The research team, led by Olivia M. Shorthouse and Juan F. Quintana, set out to answer a deceptively simple question. Reproductive dysfunction has been reported anecdotally in both human patients and experimental animals infected with T. brucei, but nobody knew whether the parasites actually entered the female reproductive tract or whether the observed problems were merely secondary effects of systemic illness. By tracking parasite localisation during both acute and chronic stages of infection in mice, the investigators demonstrated that the organisms take up residence in the endometrium, the specialised mucosal lining of the uterus. This direct infiltration of reproductive tissue places the parasite in intimate contact with the immune cells and hormone-responsive epithelium that govern fertility.

What the parasites do once they arrive proved to be as important as where they settle. The study revealed a progressive and multi-layered deterioration of reproductive health as infection moved from its acute phase into chronicity. Chronically infected mice lost substantial fat mass, a sign of the metabolic wasting characteristic of trypanosome disease. Their oestrous cycles, the rodent equivalent of the menstrual cycle, became disrupted and eventually arrested. The uterus and ovaries themselves shrank, showing measurable atrophy. Perhaps most strikingly, the researchers documented extensive transcriptional dysregulation across the hypothalamic-pituitary-gonadal axis, the hormonal control circuit that links the brain to the gonads and orchestrates fertility from the top down.

The hypothalamic-pituitary-gonadal axis is a delicate three-tiered system. The hypothalamus, a small region at the base of the brain, releases gonadotropin-releasing hormone in pulses that instruct the pituitary gland to secrete luteinising hormone and follicle-stimulating hormone. These hormones, in turn, act on the ovaries to drive follicle development, ovulation, and the production of oestrogen and progesterone. The new findings show that chronic T. brucei infection distorts gene expression at every level of this hierarchy, implying that the parasite does not merely damage the uterus locally but interferes with the central neuroendocrine commands that regulate it. This systemic rewiring of reproductive control represents a form of pathology that has rarely been characterised in parasitic infection.

Immune remodelling within the uterus emerged as a central feature of the disease process. In both acute and chronic infection, the researchers observed infiltration of T cells into uterine tissue and activation of pro-inflammatory myeloid cells, the innate immune population that includes monocytes, macrophages, and their inflammatory descendants. Beyond the uterus itself, the team detected broader type 1 inflammatory signatures spreading across reproductive tissues and components of the hypothalamic-pituitary-gonadal axis. Type 1 inflammation, typically driven by interferon signalling and associated with defence against intracellular pathogens, is not normally the dominant immune tone of the reproductive tract, which tends to favour tolerance and controlled responses. Its expansion here suggests that the infection fundamentally reprograms the immunological identity of the female reproductive organs.

The ovaries told their own story of damage. Examination of ovarian pathology revealed follicular degeneration, meaning the structures that house and nurture developing eggs were deteriorating. The researchers also counted a reduction in corpora lutea, the transient endocrine structures that form after ovulation and produce the progesterone needed to support early pregnancy. Fewer corpora lutea indicate fewer successful ovulations, a direct readout of impaired fertility. Alongside these structural changes, alterations to steroidogenic pathways were detected, pointing to disruption of the enzymatic machinery that converts cholesterol into the steroid hormones essential for cyclicity and reproduction.

One of the most compelling experiments in the study involved a therapeutic intervention designed to disentangle two competing explanations. If the uterine damage were driven purely by falling oestrogen levels, then restoring oestrogen signalling should rescue the tissue. The researchers treated infected mice with tamoxifen, a selective oestrogen receptor modulator widely known for its use in breast cancer therapy. The results were revealing but partial. Tamoxifen restored uterine morphology and prevented the arrest of the oestrous cycle, demonstrating that endocrine dysfunction is indeed a major driver of the structural collapse of the uterus. However, the hormone treatment did not reverse the infection-induced remodelling of the uterine immune environment. The inflammatory cell populations and their activation states persisted despite hormonal rescue.

This dissociation carries a significant conceptual message: endocrine dysfunction and infection-driven inflammation are two distinct processes, each contributing to reproductive pathology through separate routes. Hormonal collapse explains the loss of normal uterine architecture and cyclicity, but the immune reprogramming is a direct consequence of the infection itself and cannot be corrected simply by fixing the hormonal signal. For patients, this implies that treating the hormonal consequences of chronic parasitic disease may not be sufficient to restore full reproductive health unless the underlying inflammatory drive, and ideally the infection itself, is also addressed. It also raises the possibility that immune-mediated damage to the reproductive tract could outlast or operate independently of the visible endocrine symptoms.

The broader significance of the work lies in what it says about systemic infection as a whole. The female reproductive tract is an immunologically dynamic organ that must balance defence against pathogens with the tolerance required for successful reproduction. The new findings identify it as a major target of T. brucei infection and demonstrate how a chronic parasitic disease can disrupt reproductive physiology through a combination of immune, endocrine, and metabolic pathways acting in parallel. Fat wasting, hypothalamic dysregulation, ovarian degeneration, and uterine inflammation are not isolated phenomena but interconnected consequences of a systemic infection that reaches into every tier of reproductive control. The authors suggest that this interplay between metabolism, immunity, and endocrinology may be relevant well beyond trypanosomiasis.

Indeed, the study closes with a methodological warning for the wider research community. Because the female reproductive tract has been so frequently overlooked in models of systemic inflammation, the effects of other infectious and inflammatory diseases on fertility and reproductive endocrinology may be underappreciated. The researchers argue that future studies of systemic inflammatory conditions should specifically assess the female reproductive tract rather than assuming it is a passive bystander. For sleeping sickness, a disease that affects tens of thousands of people in sub-Saharan Africa, the findings open a new dimension of clinical concern and a new set of questions about how parasitic infection shapes long-term reproductive health in survivors. They also provide a framework for investigating whether other chronic infections quietly inflict similar damage on the reproductive system.

Subject of Research: Trypanosoma brucei infection of the female reproductive tract and its effects on uterine immunity and reproductive hormone regulation

Article Title: Trypanosoma brucei infection remodels the uterine immune environment and drives neuroendocrine dysfunction

Article References: Shorthouse, O. M., Barnes, C., Colombo, S. A. P., Costa, J., Wonsbek, K., Mohon, A., MacDonald, A. S., Mann, E., Costain, A. H., & Quintana, J. F. (2026). Trypanosoma brucei infection remodels the uterine immune environment and drives neuroendocrine dysfunction. PLOS Pathogens, 22(10), e1014667. https://doi.org/10.1371/journal.ppat.1014667

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014667

Keywords: Trypanosoma brucei, sleeping sickness, uterus, endometrium, reproductive immunology, hypothalamic-pituitary-gonadal axis, oestrous cycle, ovarian pathology, tamoxifen, inflammation, parasitology, PLOS Pathogens

Ovarian microcystic stromal tumor is exceptionally rare. Since it was first delineated as a distinct entity, only a limited number of cases have been documented in the medical literature worldwide. The tumor belongs to the broad family of ovarian stromal neoplasms, which arise from the supportive tissue of the ovary rather than from the egg cells themselves. What distinguishes MCST is its striking microscopic appearance: the tumor is composed of sheets and nests of relatively uniform cells arranged around a network of tiny, fluid-filled microcysts that give the lesion its name. Under the microscope, this architecture can resemble other ovarian tumors, including yolk sac tumor or even certain metastatic cancers, which historically made diagnosis challenging.

The key to recognizing MCST lies in its immunohistochemical fingerprint. Tumor cells in these lesions characteristically show nuclear expression of β-catenin, a protein that serves as a hallmark feature and helps separate MCST from its many microscopic mimics. The tumors also typically express Cyclin D1, CD10, vimentin, WT1, FOXL2, and SF1, a constellation of markers that pathologists use to confirm the diagnosis and to exclude other possibilities. Despite this growing list of identifying features, the biological behavior and molecular underpinnings of MCST remain incompletely characterized, largely because so few cases exist to study. Most reported tumors have behaved in a benign fashion, and conservative surgical management has generally proven sufficient.

The newly reported case involved a 38-year-old woman who had never been pregnant and who carried a history of irregular menstruation. Her ovarian mass was discovered incidentally, meaning it was found without the patient having shown symptoms directly attributable to the tumor. An initial intraoperative frozen-section examination pointed to a benign sex cord-stromal tumor, allowing the surgical team to proceed with a laparoscopic tumor enucleation, a fertility-sparing approach in which the tumor is shelled out while the ovary is preserved. This minimally invasive strategy reflects the growing recognition that, in carefully selected patients with apparently benign ovarian lesions, organ-preserving surgery can offer excellent outcomes without the need for more radical procedures.

Definitive histopathological examination confirmed the diagnosis of microcystic stromal tumor. The tumor displayed the characteristic morphology and the expected immunoprofile, with positivity for β-catenin, Cyclin D1, CD10, vimentin, WT1, FOXL2, and SF1. But two findings set this case apart. First, the tumor cells showed partial positivity for S100, a calcium-binding protein commonly expressed in neural, melanocytic, and certain other tissues, and one that is not typically associated with MCST. Second, and perhaps more strikingly, the tumor exhibited what the authors describe as a distinctive hormone receptor signature: androgen receptor was strongly expressed in approximately 90 percent of tumor cell nuclei, while progesterone receptor was weak, present in only about 15 percent of cells.

Androgen receptor expression in ovarian tumors carries particular interest because the androgen receptor participates in signaling pathways relevant to ovarian physiology and ovarian carcinogenesis. Its strong expression in this MCST raises questions about whether hormone signaling might play a role in the growth or regulation of these tumors, or whether the finding represents an incidental epiphenomenon without clinical consequence. Similarly, S100 expression introduces a diagnostic wrinkle: S100 positivity can suggest alternative diagnoses, including neural tumors or melanocytic lesions, and its partial presence in an otherwise classic MCST underscores the importance of interpreting immunohistochemical panels in context rather than relying on any single marker. Although androgen receptor expression has been reported in MCST before, and focal S100 positivity has been documented in at least one prior case, the co-existence of both features in a single tumor has only rarely been recorded.

The clinical course of the patient adds a reassuring dimension to the report. Following her laparoscopic enucleation, she recovered well, and follow-up at 28 months revealed no evidence of recurrence. This outcome is consistent with the prevailing understanding of MCST as a typically indolent neoplasm, and it supports the feasibility of conservative surgery combined with careful long-term surveillance in affected patients. For a young woman whose tumor was detected before any malignant transformation or complication, the preservation of ovarian tissue represents a meaningful quality-of-life benefit, and the extended recurrence-free follow-up provides additional confidence in the benign trajectory of this tumor type.

The authors of the report paired their case with a review of the existing literature, aiming to consolidate what is known about the clinicopathological features of MCST and its unusual immunophenotypic variants. Because the entity is so rare, individual case reports effectively serve as the primary source of knowledge, each one contributing data points that slowly refine the diagnostic criteria and the understanding of biological behavior. The review situates the present case within this accumulating record, noting both the consistency of core features—microcystic architecture, nuclear β-catenin, and benign behavior—and the variability in secondary findings such as hormone receptor status and unexpected marker expression.

The report also highlights the practical implications for diagnostic pathology. Pathologists confronting an ovarian microcystic lesion must distinguish MCST from a differential diagnosis that includes yolk sac tumor, juvenile granulosa cell tumor, and clear cell carcinoma, among others. Unusual immunostaining results, such as partial S100 positivity, could easily send the diagnostic workup down an erroneous path if not weighed against the full morphological and immunophenotypic picture. Cases like this one, in which atypical marker expression arises within an otherwise typical tumor, help calibrate the diagnostic thresholds that practicing pathologists apply, reducing the risk of both overdiagnosis and missed diagnosis.

For now, the biological significance of the combined androgen receptor and S100 expression observed in this tumor remains unresolved. The authors emphasize that larger case series will be needed to determine whether such immunophenotypic variation carries any prognostic or therapeutic relevance, or whether it simply reflects the natural heterogeneity of a rare neoplasm. In the meantime, the case stands as a reminder of how much remains to be learned about even the quietest corners of tumor biology—and of how a single carefully documented patient can meaningfully advance the field. The 28-month disease-free outcome offers comfort to patients facing similar diagnoses, while the unusual molecular profile offers scientists a fresh line of inquiry into the mechanisms that drive this enigmatic ovarian tumor.

Subject of Research: A rare benign ovarian stromal neoplasm exhibiting an atypical immunophenotype with androgen receptor and partial S100 expression

Article Title: Ovarian microcystic stromal tumor with unusual expression of AR and partial S100: a case report and literature review

Article References: Liu, M., Sun, Y., Yin, J., Liu, K., & Jiang, Z. (2026). Ovarian microcystic stromal tumor with unusual expression of AR and partial S100: a case report and literature review. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02276-7

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02276-7

Keywords: ovarian tumor, microcystic stromal tumor, MCST, androgen receptor, S100, β-catenin, immunohistochemistry, sex cord-stromal tumor, case report, ovarian pathology, laparoscopic surgery, Journal of Ovarian Research